CD4 Response to Duffy-Binding-Like Domain 2β of PfEMP1 Recombinant Protein for Malaria Vaccine Development
DOI:
https://doi.org/10.22373/ekw.v12.i2.35878Keywords:
CD4, immune response, malaria vaccine, Plasmodium falciparumAbstract
Abstract: A malaria vaccine based on Plasmodium falciparum antigen is essential in controlling malaria morbidity and mortality. The Duffy-binding-like domain 2β of Plasmodium falciparum erythrocyte membrane protein 1 (DBL2β-PfEMP1) is a malaria subunit vaccine candidate expected to prevent severe malaria. Meanwhile, subunit vaccines often elicit a weak immune response. This study aimed to analyze the CD4 response induced by several doses of DBL2β-PfEMP1 recombinant protein injection. This was a post-test-only true experimental study using 30 male Wistar rats (Rattus norvegicus) aged 2-3 months, weighing 150-250 g. The rats were randomly assigned into two control groups: NaCl 0.9% and adjuvant groups, and four treatment groups: DBL2β-PfEMP1 0.75 mg/kgBW, 0.75 mg/kgBW + adjuvant, 1.5 mg/kgBW + adjuvant, and 2.25 mg/kgBW + adjuvant groups. Injection was performed subcutaneously twice on days 0 and 42, and the blood serum was collected on days 14 and 56 for CD4 measurement using an enzyme-linked immunosorbent assay (ELISA) method. The results showed that CD4 concentration tends to decrease with an increasing dose of the DBL2β-PfEMP1 protein, particularly in post-injection II. Analysis of the differences between groups using the Kruskal-Wallis test showed no significant differences with p=0.59 in post-injection I and p=0.68 in post-injection II, and the Wilcoxon signed rank test to examine the differences across injections within each group showed no significant differences (p>0.05) in all groups. The results indicated no statistically significant differences in CD4 concentration post DBL2β-PfEMP1 recombinant protein injection in Wistar rats. Further studies examining other induced immune responses should be conducted to emphasize the DBL2β-PfEMP1 recombinant protein as a malaria vaccine candidate.
Abstrak: Vaksin malaria berbasis antigen Plasmodium falciparum penting untuk mengendalikan morbiditas dan mortalitas akibat malaria. Duffy-binding-like domain 2β dari Plasmodium falciparum Erythrocyte Membrane Protein 1 (DBL2β-PfEMP1) merupakan salah satu kandidat vaksin malaria subunit yang diharapkan mampu mencegah malaria berat. Namun, umumnya vaksin subunit menginduksi respon imun yang lemah. Penelitian ini bertujuan untuk menganalisis respon CD4 setelah injeksi beberapa dosis protein rekombinan DBL2β-PfEMP1. Sebanyak 30 tikus Wistar jantan berusia 2-3 bulan dengan berat 150-250 g dibagi ke dalam dua kelompok kontrol: NaCl dan adjuvan, dan empat kelompok perlakuan: DBL2β-PfEMP1 0,75 mg/kgBB, 0,75 mg/kgBB + adjuvan, 1,5 mg/kgBB + adjuvan, and 2,25 mg/kgBB + adjuvan. Injeksi subkutan dilakukan dua kali pada hari ke-0 dan 42. Serum dikoleksi pada hari ke-14 dan 56 untuk pemeriksaan CD4 menggunakan metode ELISA. Hasil pengukuran menunjukkan bahwa konsentrasi CD4 cenderung menurun seiring dengan peningkatan dosis protein rekombinan, terutama setelah injeksi II. Analisis perbedaan tiap kelompok menggunakan Kruskal-Wallis test menunjukkan tidak ada perbedaan yang signifikan dengan p=0,59 setelah injeksi I dan p=0,68 setelah injeksi II. Dan analisis menggunakan Wilcoxon signed rank test untuk menilai perbedaan tiap kelompok antar injeksi menunjukkan semua kelompok tidak ada perbedaan bermakna (p>0,05). Hasil ini mengindikasikan bahwa injeksi protein rekombinan DBL2β-PfEMP1 menginduksi respon CD4 yang tidak signifikan. Penelitian lanjutan dengan menilai respon imun lain diperlukan untuk menekankan potensi protein ini sebagai kandidat vaksin malaria.
References
Barrett, J. R., Silk, S. E., Mkindi, C. G., Kwiatkowska, K. M., Hou, M. M., Lias, A. M., Kalinga, W. F., Mtaka, I. M., McHugh, K., Bardelli, M., Davies, H., King, L. D. W., Edwards, N. J., Chauhan, V. S., Mukherjee, P., Rwezaula, S., Chitnis, C. E., Olotu, A. I., Minassian, A. M., … Nielsen, C. M. (2023). Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1193079
Billeskov, R., Beikzadeh, B., & Berzofsky, J. A. (2019). The effect of antigen dose on T cell-targeting vaccine outcome. In Human Vaccines and Immunotherapeutics (Vol. 15, Number 2). https://doi.org/10.1080/21645515.2018.1527496
Billeskov, R., Wang, Y., Solaymani-Mohammadi, S., Frey, B., Kulkarni, S., Andersen, P., Agger, E. M., Sui, Y., & Berzofsky, J. A. (2017). Low Antigen Dose in Adjuvant-Based Vaccination Selectively Induces CD4 T Cells with Enhanced Functional Avidity and Protective Efficacy. The Journal of Immunology, 198(9). https://doi.org/10.4049/jimmunol.1600965
Björkman, A., Benn, C. S., Aaby, P., & Schapira, A. (2023). RTS,S/AS01 malaria vaccine—proven safe and effective? The Lancet Infectious Diseases, 23(8), e318–e322. https://doi.org/10.1016/S1473-3099(23)00126-3
Datoo, M. S., Dicko, A., Tinto, H., Ouédraogo, J. B., Hamaluba, M., Olotu, A., Beaumont, E., Ramos Lopez, F., Natama, H. M., Weston, S., Chemba, M., Compaore, Y. D., Issiaka, D., Salou, D., Some, A. M., Omenda, S., Lawrie, A., Bejon, P., Rao, H., … Valea, I. (2024). Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. The Lancet, 403(10426), 533–544. https://doi.org/10.1016/S0140-6736(23)02511-4
El-Moamly, A. A., & El-Sweify, M. A. (2023). Malaria vaccines: the 60-year journey of hope and final success—lessons learned and future prospects. Tropical Medicine and Health, 51(1). https://doi.org/10.1186/s41182-023-00516-w
Greenfield, E. A. (2020). Standard immunization of mice, rats, and hamsters. Cold Spring Harbor Protocols, 2020(3): 100297. doi:10.1101/pdb.prot100297
Jensen, A. R., Adams, Y., & Hviid, L. (2020). Cerebral Plasmodium falciparum malaria: The role of PfEMP1 in its pathogenesis and immunity, and PfEMP1-based vaccines to prevent it. Immunological Reviews, 293(1), 230–252. https://doi.org/10.1111/imr.12807
Jongo, S. A., Preston Church, L. W., Mtoro, A. T., Schindler, T., Chakravarty, S., Ruben, A. J., Swanson, P. A., Kassim, K. R., Mpina, M., Tumbo, A. M., Milando, F. A., Qassim, M., Juma, O. A., Bakari, B. M., Simon, B., James, E. R., Abebe, Y., Natasha, K. C., Saverino, E., … Hoffman, S. L. (2020). Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ vaccine in Tanzanian Adults. Clinical Infectious Diseases, 71(11), 2849–2857. https://doi.org/10.1093/cid/ciz1152
Kibwana, E., Bundi, C., Kimani, D., Nyamako, L., Keter, K., Mutiso, A., Ogwang, R., Bellamy, D., Rapi, K., Bajer, A., Provstgaard-Morys, S., Stockdale, L., Munoz, O., Datoo, M. S., Lawrie, A., Ramos-Lopez, F., Roberts, R., Hamaluba, M., Hill, A. V. S., … Kapulu, M. (2025). R21/Matrix-M malaria vaccine drives diverse immune responses in pre-exposed adults: insights from a phase IIb controlled human malaria infection trial. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1620365
Lee, D. H., Chu, K. B., Kang, H. J., Lee, S. H., Chopra, M., Choi, H. J., Moon, E. K., Inn, K. S., & Quan, F. S. (2019). Protection induced by malaria virus-like particles containing codon-optimized AMA-1 of Plasmodium berghei. Malaria Journal, 18(1). https://doi.org/10.1186/s12936-019-3017-2
Lee, H. J., Moreira, M. L., Li, S., Asatsuma, T., Williams, C. G., Skinner, O. P., Asad, S., Bramhall, M., Jiang, Z., Liu, Z., Kerr, A. S., Engel, J. A., Soon, M. S. F., Straube, J., Barrera, I., Murray, E., Chen, F., Nideffer, J., Jagannathan, P., & Haque, A. (2024). CD4+ T cells display a spectrum of recall dynamics during re-infection with malaria parasites. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-49879-6
Mandala, W. L., Harawa, V., Dzinjalamala, F., & Tembo, D. (2021). The role of different components of the immune system against Plasmodium falciparum malaria: Possible contribution towards malaria vaccine development. Molecular and Biochemical Parasitology, 246, 111425. https://doi.org/10.1016/j.molbiopara.2021.111425
McNamara, H. A., Idris, A. H., Sutton, H. J., Vistein, R., Flynn, B. J., Cai, Y., Wiehe, K., Lyke, K. E., Chatterjee, D., KC, N., Chakravarty, S., Lee Sim, B. K., Hoffman, S. L., Bonsignori, M., Seder, R. A., & Cockburn, I. A. (2020). Antibody Feedback Limits the Expansion of B Cell Responses to Malaria Vaccination but Drives Diversification of the Humoral Response. Cell Host and Microbe, 28(4). https://doi.org/10.1016/j.chom.2020.07.001
Mitchell, R. A., Macià, D., Jairoce, C., Mpina, M., Naidu, A., Chopo-Pizarro, A., Vázquez-Santiago, M., Campo, J. J., Aide, P., Aguilar, R., Daubenberger, C., Dobaño, C., & Moncunill, G. (2024). Effect of RTS,S/AS01E vaccine booster dose on cellular immune responses in African infants and children. Npj Vaccines, 9(1). https://doi.org/10.1038/s41541-024-00977-y
Palgen, J. L., Feraoun, Y., Dzangué-Tchoupou, G., Joly, C., Martinon, F., Le Grand, R., & Beignon, A. S. (2021). Optimize Prime/Boost Vaccine Strategies: Trained Immunity as a New Player in the Game. In Frontiers in Immunology (Vol. 12). Frontiers Media S.A. https://doi.org/10.3389/fimmu.2021.612747
Rachmania, S., Sulistyaningsih, E., & Ratna Dewi, A. A. I. (2021). Recombinant DBL2β-PfEMP1 of the Indonesian Plasmodium falciparum induces immune responses in Wistar rats. Journal of Taibah University Medical Sciences, 16(3), 422–430. https://doi.org/10.1016/j.jtumed.2020.12.007
Rhodes, S. J., Knight, G. M., Kirschner, D. E., White, R. G., & Evans, T. G. (2019). Dose finding for new vaccines: The role for immunostimulation/immunodynamic modelling. In Journal of Theoretical Biology (Vol. 465). https://doi.org/10.1016/j.jtbi.2019.01.017
Suurbaar, J., Moussiliou, A., Tahar, R., Olsen, R. W., Adams, Y., Dalgaard, N., Baafour, E. K., Adukpo, S., Hviid, L., Kusi, K. A., Alao, J., Ofori, M. F., Ndam, N. T., & Jensen, A. R. (2022). OPEN ICAM 1 binding Plasmodium falciparum erythrocyte membrane protein 1 variants elicits opsonic phagocytosis IgG responses in Beninese children. Scientific Reports, 1–12. https://doi.org/10.1038/s41598-022-16305-0
WHO. (2023). World malaria report 2023. World Health Organization. Geneva. ISBN 978-92-4-008617-3. https://apps.who.int/iris.
Wiser, M. F. (2023). Knobs, Adhesion, and Severe Falciparum Malaria. Tropical Medicine and Infectious Disease, 8(7). https://doi.org/10.3390/tropicalmed8070353
Yao, P. F., Zhang, P. J., Dong, H., & Sun, Y. (2021). Acute colonic pseudo-obstruction in severe falciparum malaria: A case report. Journal of Medical Cases, 12(12), 481–484. https://doi.org/10.14740/jmc3801
Zaric, M., Marini, A., Nielsen, C. M., Gupta, G., Mekhaiel, D., Pham, T. P., Elias, S. C., Taylor, I. J., de Graaf, H., Payne, R. O., Li, Y., Silk, S. E., Williams, C., Hill, A. V. S., Long, C. A., Miura, K., & Biswas, S. (2021). Poor CD4+ T Cell Immunogenicity Limits Humoral Immunity to P. falciparum Transmission-Blocking Candidate Pfs25 in Humans. Frontiers in Immunology, 12. https://doi.org/10.3389/fimmu.2021.732667
Zelter, T., Strahilevitz, J., Simantov, K., Yajuk, O., Jensen, A. R., Dzikowski, R., & Granot, Z. (2021). Neutrophils impose strong selective pressure against PfEMP1 variants implicated in cerebral malaria. BioRxiv. https://doi.org/doi.org/10.1101/2021.05.09.443317
Published
Issue
Section
License
Copyright (c) 2026 Erma Sulistyaningsih, Tsabita Nafisa, Rosita Dewi, Sheilla Rachmania, Irawan Fajar Kusuma

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Proposed Policy for Journals That Offer Open Access Authors who publish with the Elkawnie journal agree to the following terms:
a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).



